AVITA Medical(US:RCEL)2026-02-12 22:20Financial Performance - Total revenues increased by 11%, or $7.4 million, to $71.6 million for the year ended December 31, 2025, compared to $64.3 million in 2024[197] - Total revenues increased by 28%, or $14.1 million, to $64.3 million for the year ended December 31, 2024, compared to $50.1 million in the prior year[205] - Net loss decreased by $13.3 million to $48.6 million, compared to a net loss of $61.8 million in the previous year[204] Gross Profit and Margins - Gross profit margin was 82.1%, down from 85.8% in the prior year, primarily due to product mix and higher inventory reserve[198] - Gross profit increased by 30%, or $12.8 million, to $55.2 million, resulting in a gross profit margin of 85.8%[205][206] Operating Expenses - Total operating expenses decreased by 9%, or $10.4 million, to $101.4 million compared to $111.8 million in 2024[199] - Sales and marketing expenses decreased by 9%, or $5.1 million, to $53.1 million, attributed to reductions in salaries, stock-based compensation, and travel expenses[200] - General and administrative expenses decreased by 18%, or $5.8 million, to $27.3 million, primarily due to lower stock-based compensation and salaries[201] - Total operating expenses increased by 29%, or $25.3 million, to $111.8 million, compared to $86.4 million in the prior year[208] - Sales and marketing expenses rose by 56%, or $20.9 million, to $58.2 million, driven by increased personnel costs and expansion of the sales force[209] - General and administrative expenses increased by 17%, or $4.9 million, to $33.1 million, primarily due to headcount growth and stock-based compensation[210] - Research and development expenses increased by 2%, or $0.5 million, to $20.8 million, driven by higher salaries and stock-based compensation[202] - Research and development expenses decreased by 2%, or $0.5 million, to $20.3 million, mainly due to lower professional fees[211] Cash Flow and Financing - The company had approximately $10.2 million in cash and cash equivalents and $7.9 million in marketable securities as of December 31, 2025[215] - For the year ended December 31, 2025, net cash used in operating activities was $31.2 million, a decrease from $48.9 million in 2024, primarily due to higher gross profit and lower operating costs[229] - Net cash provided by investing activities decreased to $12.5 million in 2025 from $37.4 million in 2024, attributed to lower cash inflows from maturities of marketable securities and reduced capital expenditures[230] - Net cash provided by financing activities increased significantly to $14.9 million in 2025 from $3.5 million in 2024, driven by net proceeds from a Placement[231] - The company closed a five-year credit facility providing up to $60 million in capital, with initial TTM revenue covenants set at $68.5 million for Q1 2026[186] - A new credit agreement was entered into on January 13, 2026, providing a senior secured credit facility of up to $60 million[217] Regulatory Approvals and Product Development - The Centers for Medicare & Medicaid Services approved a New Technology Add-On Payment for the RECELL® System, allowing up to $4,875 in additional reimbursement per case[189] - RECELL GO mini was approved by the FDA in December 2024, designed for treating smaller wounds up to 480 cm², enhancing the RECELL GO platform[180] - The company aims to increase market penetration in U.S. burn centers and expand adoption of RECELL for traumatic and surgical wounds[182] Tax and Accounting - Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between financial statement carrying amounts and their respective tax bases[261] - The company regularly reviews its uncertain tax positions, recognizing tax benefits when it is more-likely-than-not that the position will be sustained[262] - The revenue recognition for the RECELL GO product is disaggregated between ASC 606 for RPKs and ASC 842 for RPD[239] - The company has elected the fair value option for accounting under ASC 825-10 for its loan facility, allowing for remeasurement every reporting period[257] - The fair value of the loan facility was determined using a Monte Carlo simulation, capturing different potential cash flow outcomes[258] Shareholder and Dividend Policy - The company has no plans to commence the payment of dividends, with no dividends paid for the year ended December 31, 2025[233] - The company has never paid cash dividends and does not expect to pay any in the foreseeable future[258] Miscellaneous - The company accrued $2.0 million related to 510(k) clearance received on December 19, 2024, with an additional obligation of up to $3.0 million contingent on clinical study results[234] - The company aims to maintain a capital structure that ensures the lowest cost of capital available, regularly reviewing opportunities to improve outcomes for stakeholders[232] - The trailing 12-month revenue covenant for the fourth quarter of 2024 was removed, which was previously set at $67.5 million[228] - The company issued warrants to purchase up to 145,180 shares of common stock at an exercise price of $0.01 per share as part of the Fourth Amendment to the Previous Credit Agreement[227] - The company has no material off-balance sheet arrangements that could affect its financial condition or results of operations[235] - The fair value of warrants is recorded as a liability and subject to re-measurement at each settlement date[256] - The company uses the Black-Scholes option pricing model to estimate the fair value of warrant liabilities[256] - The expected term of stock options is determined using the "simplified" method due to limited historical exercise experience[258] - The company has limited historical option exercise experience due to its short operating history, with the first plan established in 2016[258] - As a smaller reporting company, the company is not required to provide detailed market risk disclosures[265]